Tibolone and Breast Cancer

키워드

참고문헌 (44)

1. Rossouw JE, "Risks and benefits of estrogen plus progestin in healthy postmenopausal women : principal results from the Women’s Health Initiative randomized controlled trial", JAMA, 288, pp.321~333 (2002)
2. Chlebowski RT, "Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women : the Women’s Health Initiative Randomized Trial", JAMA, 289, pp.3243~3253 (2003)
3. Anderson GL, "Prior hormone therapy and breast cancer risk in the Women’s Health Initiative randomized trial of estrogen plus progestin", Maturitas, 55, pp.103~115 (2006)
4. Heiss G, "Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin", JAMA, 299, pp.1036~1045 (2008)
5. Manson JE, "Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials", JAMA, 310, pp.1353~1368 (2013)
6. Chlebowski RT, "Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the Women’s Health Initiative randomized clinical trials", JAMA, 324, pp.369~380 (2020)
7. The 2022 Hormone Therapy Position Statement of The North American Menopause SocietyAdvisory Panel, "The 2022 hormone therapy position statement of The North American Menopause Society", Menopause, 29, pp.767~794 (2022)
8. Fournier A, "Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort", Int J Cancer, 114, pp.448~454 (2005)
9. Reed MJ, "Tibolone : a selective tissue estrogenic activity regulator(STEAR)", Maturitas, 48(Suppl 1), pp.S4~S6 (2004)
10. Kloosterboer HJ, "Tissue-selectivity : the mechanism of action of tibolone", Maturitas, 48(Suppl 1), pp.S30~S40 (2004)
11. Kenemans P, "Tibolone : clinical recommendations and practical guidelines. A report of the International Tibolone Consensus Group", Maturitas, 51, pp.21~28 (2005)
12. Huang KE, "Updated clinical recommendations for the use of tibolone in Asian women", Climacteric, 13, pp.317~327 (2010)
13. Mendoza N, "Spanish Menopause Society position statement : use of tibolone in postmenopausal women", Menopause, 20, pp.754~760 (2013)
14. Biglia N, "Tibolone in postmenopausal women : a review based on recent randomised controlled clinical trials", Gynecol Endocrinol, 26, pp.804~814 (2010)
15. Lello S, "Tibolone and breast tissue : a review", Reprod Sci, 30, pp.3403~3409 (2023)
16. Del Río JP, "Tibolone as hormonal therapy and neuroprotective agent", Trends Endocrinol Metab, 31, pp.742~759 (2020)
17. Wang PH, "Effects of tibolone on the breast of postmenopausal women", Taiwan J Obstet Gynecol, 46, pp.121~126 (2007)
18. Erel CT, "Tibolone and breast cancer", Postgrad Med J, 82, pp.658~662 (2006)
19. Palomba S, "Effect of tibolone on breast symptoms resulting from postmenopausal hormone replacement therapy", Maturitas, 45, pp.267~273 (2003)
20. von Schoultz B, "The effects of tibolone and oestrogen-based HT on breast cell proliferation and mammographic density", Maturitas, 49, pp.S16~21 (2004)
21. Valdivia I, "Mammographic density in postmenopausal women treated with tibolone, estriol or conventional hormone replacement therapy", Clin Drug Investig, 20, pp.101~107 (2000)
22. Colacurci N, "Effects of different types of hormone replacement therapy on mammographic density", Maturitas, 40, pp.159~164 (2001)
23. Valdivia I, "Effects of tibolone and continuous combined hormone therapy on mammographic breast density and breast histochemical markers in postmenopausal women", Fertil Steril, 81, pp.617~623 (2004)
24. Christodoulakos GE, "Mammographic changes associated with raloxifene and tibolone therapy in postmenopausal women : a prospective study", Menopause, 9, pp.110~116 (2002)
25. Tice JA, "Using clinical factors and mammographic breast density to estimate breast cancer risk : development and validation of a new predictive model", Ann Intern Med, 148, pp.337~347 (2008)
26. Bodewes FTH, "Mammographic breast density and the risk of breast cancer : a systematic review and meta-analysis", Breast, 66, pp.62~68 (2022)
27. Kloosterboer HJ, "Tibolone : a steroid with a tissue-specific mode of action", J Steroid Biochem Mol Biol, 76, pp.231~238 (2001)
28. Escande A, "Regulation of activities of steroid hormone receptors by tibolone and its primary metabolites", J Steroid Biochem Mol Biol, 116, pp.8~14 (2009)
29. Swegle JM, "Tibolone : a unique version of hormone replacement therapy", Ann Pharmacother, 38, pp.874~881 (2004)
30. Chetrite G, "Effect of tibolone(Org OD14)and its metabolites on estrone sulphatase activity in MCF-7 and T-47D mammary cancer cells", Anticancer Res, 17, pp.135~140 (1997)
31. Chetrite GS, "Effects of Org OD14(Livial)and its metabolites on 17 beta-hydroxysteroid dehydrogenase activity in hormone-dependent MCF-7 and T-47D breast cancer cells", Anticancer Res, 19, pp.261~267 (1999)
32. Chetrite GS, "Effect of tibolone and its principal metabolites(3α-and 3β-hydroxy, 3α-sulfate, and 4-ene derivatives)on estrone sulfatase activity in normal and cancerous human breast tissue", Horm Mol Biol Clin Investig, 8, pp.491~498 (2011)
33. Falany JL, "Sulfation of tibolone and tibolone metabolites by expressed human cytosolic sulfotransferases", J Steroid Biochem Mol Biol, 88, pp.383~391 (2004)
34. Gompel A, "In vitro studies of tibolone in breast cells", Fertil Steril, 78, pp.351~359 (2002)
35. Beral V, "Breast cancer and hormone-replacement therapy in the Million Women Study", Lancet, 362, pp.419~427 (2003)
36. Shapiro S, "The Million Women Study : potential biases do not allow uncritical acceptance of the data", Climacteric, 7, pp.3~7 (2004)
37. Whitehead M, "The million women study : a critique", Endocrine, 24, pp.187~193 (2004)
38. Opatrny L, "Hormone replacement therapy use and variations in the risk of breast cancer", BJOG, 115, pp.169~175 (2008)
39. Cummings SR, "The effects of tibolone in older postmenopausal women", N Engl J Med, 359, pp.697~708 (2008)
40. Formoso G, "Short-term and long-term effects of tibolone in postmenopausal women", Cochrane Database Syst Rev, 10, pp.CD008536~ (2016)
41. Kenemans P, "Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms : a double-blind, randomised, non-inferiority trial", Lancet Oncol, 10, pp.135~146 (2009)
42. Cordina-Duverger E, "Risk of breast cancer by type of menopausal hormone therapy : a case-control study among post-menopausal women in France", PLoS One, 8, pp.e78016~ (2013)
43. Román M, "Postmenopausal hormone therapy and the risk of breast cancer in Norway", Int J Cancer, 138, pp.584~593 (2016)
44. Baek JK, "Relationship between the type of hormone replacement therapy and incidence of breast cancer in Korea", Climacteric, 25, pp.516~522 (2022)

관련 논문AI추천